About Hi-Tech Pharmacal (NASDAQ:HITK)
Hi-Tech Pharmacal Co., Inc. is a specialty manufacturer and marketer of prescription, over-the-counter and nutritional products. The Company develops, manufactures and markets products in three categories: generics, prescription brands and over-the-counter (OTC) brands. It produces a range of products for various disease states, including glaucoma, asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care and other conditions. The Company's generic products are primarily prescription items and include oral solutions and suspensions, topical creams and ointments as well as nasal sprays. It also specializes in the manufacture of products in its sterile facility capable of producing liquid ophthalmic, otic and inhalation products. In April 2014, Akorn Inc acquired Hi-Tech Pharmacal Co., Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:HITK
- CUSIP: 42840B10
- Web: N/A
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 15.76
- P/E Growth: N/A
Frequently Asked Questions for Hi-Tech Pharmacal (NASDAQ:HITK)
What is Hi-Tech Pharmacal's stock symbol?
Hi-Tech Pharmacal trades on the NASDAQ under the ticker symbol "HITK."
Who are some of Hi-Tech Pharmacal's key competitors?
Some companies that are related to Hi-Tech Pharmacal include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis AG (NVS), Merck & Company (MRK), Amgen (AMGN), Novo Nordisk A/S (NVO), Sanofi (SNY), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Celgene Corporation (CELG), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP) and Teva Pharmaceutical Industries Limited (TEVA).
How do I buy Hi-Tech Pharmacal stock?
Shares of Hi-Tech Pharmacal can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Hi-Tech Pharmacal's stock price today?
MarketBeat Community Rating for Hi-Tech Pharmacal (NASDAQ HITK)MarketBeat's community ratings are surveys of what our community members think about Hi-Tech Pharmacal and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Hi-Tech Pharmacal stock can currently be purchased for approximately $43.49.
Consensus Ratings for Hi-Tech Pharmacal (NASDAQ:HITK) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Hi-Tech Pharmacal (NASDAQ:HITK)
Analysts' Ratings History for Hi-Tech Pharmacal (NASDAQ:HITK)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Hi-Tech Pharmacal (NASDAQ:HITK)Earnings History by Quarter for Hi-Tech Pharmacal (NASDAQ HITK)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/11/2014||Q314||$0.66||$0.70||$62.35 million||$59.90 million||View||N/A|
|12/10/2013||Q2||$0.47||$0.71||$57.97 million||$58.60 million||View||N/A|
|9/9/2013||Q1 2014||$0.44||$0.44||$57.78 million||$50.50 million||View||Listen|
|7/9/2013||Q4 2013||$0.63||$0.50||$66.33 million||$58.50 million||View||Listen|
|3/7/2013||Q3 2013||$0.71||$0.43||$60.45 million||$64.33 million||View||Listen|
|9/5/2012||Q113||$0.68||$0.44||$57.60 million||$52.00 million||View||N/A|
|12/9/2010||$0.56||$0.76||$42.47 million||$44.90 million||View||N/A|
Earnings Estimates for Hi-Tech Pharmacal (NASDAQ:HITK)
Current Year EPS Consensus Estimate: $2.38 EPS
Next Year EPS Consensus Estimate: $2.76 EPS
Dividend History for Hi-Tech Pharmacal (NASDAQ:HITK)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Hi-Tech Pharmacal (NASDAQ:HITK)Insider Trades by Quarter for Hi-Tech Pharmacal (NASDAQ:HITK)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/13/2013||Gary April||Insider||Sell||6,873||$43.06||$295,951.38|| |
|10/10/2013||Reuben Seltzer||Chairman||Sell||11,250||$43.13||$485,212.50|| |
|10/8/2013||David Seltzer||CEO||Sell||23,000||$43.09||$991,070.00|| |
|10/4/2013||Martin Goldwyn||Director||Sell||1,500||$43.10||$64,650.00|| |
|10/3/2013||William J Peters||CFO||Sell||21,250||$43.11||$916,087.50|| |
|10/2/2013||Bruce W Simpson||Director||Sell||25,468||$43.15||$1,098,944.20|| |
|10/2/2013||Reuben Seltzer||Chairman||Sell||11,250||$43.13||$485,212.50|| |
|2/5/2013||William J Peters||CFO||Sell||4,639||$38.00||$176,282.00|| |
Headline Trends for Hi-Tech Pharmacal (NASDAQ:HITK)
Latest Headlines for Hi-Tech Pharmacal (NASDAQ:HITK)
Loading headlines, please wait.
Hi-Tech Pharmacal (HITK) Chart for Tuesday, October, 24, 2017